Sally Ibrahim Hassanein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sally Ibrahim Hassanein has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Mohamed Zakaria Gad
Biochemistry Department, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, Egypt
2 shared publications Ahmed Hegazy
German University in Cairo
1 shared publicationDina Osama
German University in Cairo
1 shared publication- Ehsan Ullah
Department of Pathology, The Ohio State University, Columbus, OH
1 shared publication Hafiz Hashmi
University College of Conventional Medicine, Faculty of Medicine and Allied Health Sciences, Islamia University Bahawalpur
1 shared publicationHala Y. Abdelnasser
Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, USA
1 shared publication
Latest Publications
- 18 February 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 399
MASLD biomarker discovery: evaluating lipidomics techniques across disease progression
- 18 February 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 399
MASLD biomarker discovery: evaluating lipidomics techniques across disease progression
- Open Access
- 23 January 2025
- Published by Wiley in Journal of Engineering and Science in Medical Diagnostics and Therapy
- Vol. 8 (2) , 1-13
The Role of Artificial Intelligence in Improving Histopathological Diagnosis of Prostate Cancer: A Review
This review investigates the effectiveness of exploiting the massive Artificial Intelligence (AI) technology in the diagnosis of prostate cancer histopathological images. It focuses on studying and analyzing the current state and practice for utilizing AI tools, including significant machine learning and deep learning models in the histopathological image analysis process. The preferred reporting items for systematic reviews and meta-analyses (PRISMA) methodology was adopted for conducting this systematic review to include recent research articles that have been published since 2017. Leveraging novel deep learning models and advanced imaging techniques, AI demonstrates promising capabilities in improving accuracy and efficiency in detecting and classifying prostate cancer. A comprehensive comparison of existing works has been presented with in-depth discussions around current limitations and key challenges while proposing some future advancements. This study aims to pave the way for future research and further integration of AI into the diagnostic processes toward early detection, personalized treatment strategies, and enhanced patient outcomes in the context of a prostate cancer diagnosis.
- 23 January 2025
- Published by Wiley in Journal of Engineering and Science in Medical Diagnostics and Therapy
- Vol. 8 (2) , 1-13
Open AccessThe Role of Artificial Intelligence in Improving Histopathological Diagnosis of Prostate Cancer: A Review
This review investigates the effectiveness of exploiting the massive Artificial Intelligence (AI) technology in the diagnosis of prostate cancer histopathological images. It focuses on studying and analyzing the current state and practice for utilizing AI tools, including significant machine learning and deep learning models in the histopathological image analysis process. The preferred reporting items for systematic reviews and meta-analyses (PRISMA) methodology was adopted for conducting this systematic review to include recent research articles that have been published since 2017. Leveraging novel deep learning models and advanced imaging techniques, AI demonstrates promising capabilities in improving accuracy and efficiency in detecting and classifying prostate cancer. A comprehensive comparison of existing works has been presented with in-depth discussions around current limitations and key challenges while proposing some future advancements. This study aims to pave the way for future research and further integration of AI into the diagnostic processes toward early detection, personalized treatment strategies, and enhanced patient outcomes in the context of a prostate cancer diagnosis.
- Open Access
- 12 June 2023
- Published by Springer Nature in Research Square
Expression of microRNA-133a and microRNA-208b in acute myocardial infarction; A randomized clinical trial
Background: Myocardial microRNAs (Myo-miR) like MiR-1, miR-133 and miR-208 are specific to cardiac muscles development and function. Diagnostic potential of MiR-1, miR-133 and miR-208 in acute episodes of myocardial infarction is unknown. Methods: Patient of newly onset of acute myocardial infarction with elevated ST-segment admitted to Ain-Shams university hospital Cairo from May 2013 to December 2022 were enrolled. Written consent was obtained. Circulating MiRNAs were measured at 04, 08, 12, 24, 48 hours from onset of angina by RT-PCR and compare with conventional creatin-kinases for diagnostic potential. Results were analyzed by student t-test, ROC curve calculations and ANOVA were performed using GraphPad-Prism-9Version. Results: 746 patients admitted with STEMI and 10(1.34%) cases were presented with new-onset episodes of STEMI with mean±SD age 54.2±8.49 year. miR-133a peaks at 8 hours, miR-208b peaks at 12 hours from onset of AMI compared to cTnI and CK-MB peak at 12hrs(P2= 0.858 P=0.47), miR-208b and cTnI (R=0.8-R2=0.64 P=0.1) , miR-208b and CK-MB was (R=0.888-R2=0.789 P=0.044) and CK-MB-cTnI (R=0.72) respectively. Conclusion: We showed miR-133a and miR-208b diagnostic specificity superior over conventional blood biomarkers for acute onset of STEMI. (NCT05692752)
- 12 June 2023
- Published by Springer Nature in Research Square
Open AccessExpression of microRNA-133a and microRNA-208b in acute myocardial infarction; A randomized clinical trial
Background: Myocardial microRNAs (Myo-miR) like MiR-1, miR-133 and miR-208 are specific to cardiac muscles development and function. Diagnostic potential of MiR-1, miR-133 and miR-208 in acute episodes of myocardial infarction is unknown. Methods: Patient of newly onset of acute myocardial infarction with elevated ST-segment admitted to Ain-Shams university hospital Cairo from May 2013 to December 2022 were enrolled. Written consent was obtained. Circulating MiRNAs were measured at 04, 08, 12, 24, 48 hours from onset of angina by RT-PCR and compare with conventional creatin-kinases for diagnostic potential. Results were analyzed by student t-test, ROC curve calculations and ANOVA were performed using GraphPad-Prism-9Version. Results: 746 patients admitted with STEMI and 10(1.34%) cases were presented with new-onset episodes of STEMI with mean±SD age 54.2±8.49 year. miR-133a peaks at 8 hours, miR-208b peaks at 12 hours from onset of AMI compared to cTnI and CK-MB peak at 12hrs(P2= 0.858 P=0.47), miR-208b and cTnI (R=0.8-R2=0.64 P=0.1) , miR-208b and CK-MB was (R=0.888-R2=0.789 P=0.044) and CK-MB-cTnI (R=0.72) respectively. Conclusion: We showed miR-133a and miR-208b diagnostic specificity superior over conventional blood biomarkers for acute onset of STEMI. (NCT05692752)
- 3 October 2018
- Published by Springer Nature in Molecular Biology Reports
- Vol. 45 (6) , 2411-2419
AGXT2 and DDAH-1 genetic variants are highly correlated with serum ADMA and SDMA levels and with incidence of coronary artery disease in Egyptians
Dimethylarginine aminodehydrolase (DDAH1) and alanine glyoxylate aminotransferase2 (AGXT2) are two enzymes that contribute in asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) metabolism. Hence they affect production and bioavailability of eNOS-derived nitric oxide (NO) and consequently healthy blood vessels. The major aims of the current study were to investigate the association of genetic variants of AGXT2 rs37369, AGXT2 rs16899974 and DDAH1 rs997251 SNPs with incidence of coronary artery disease (CAD) in Egyptians and to correlate these variants with the serum levels of ADMA and SDMA. The study included 150 subjects; 100 CAD patients and 50 healthy controls. Genotyping was performed by qPCR while the ADMA and SDMA concentrations were assayed by ELISA. Both serum ADMA and SDMA concentrations were significantly higher in CAD patients compared to controls (both p < 0.0001). Genotype distributions for all studied SNPs were significantly different between CAD patients and controls. Carriers of AGXT2 rs37369-T allele (CT + TT genotypes) and AGXT2 rs16899974-A allele (CA + AA genotypes) had 2.4- and 2.08-fold higher risk of having CAD than CC genotype in both SNPs (p = 0.0050 and 0.0192, respectively). DDAH1 rs997251 TC + CC genotypes were associated with 2.3-fold higher risk of CAD than TT genotype (p = 0.0063). Moreover, the AGXT2 rs37369 TT and AGXT2 rs16899974 AA genotypes were associated with the highest serum ADMA and SDMA while DDAH1 rs997251 CC genotype was associated with the highest ADMA. AGXT2 rs37369-T, AGXT2 rs16899974-A, and DDAH1 rs997251-C alleles represent independent risk factors for CAD in the Egyptians.
- 3 October 2018
- Published by Springer Nature in Molecular Biology Reports
- Vol. 45 (6) , 2411-2419
AGXT2 and DDAH-1 genetic variants are highly correlated with serum ADMA and SDMA levels and with incidence of coronary artery disease in Egyptians
Dimethylarginine aminodehydrolase (DDAH1) and alanine glyoxylate aminotransferase2 (AGXT2) are two enzymes that contribute in asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) metabolism. Hence they affect production and bioavailability of eNOS-derived nitric oxide (NO) and consequently healthy blood vessels. The major aims of the current study were to investigate the association of genetic variants of AGXT2 rs37369, AGXT2 rs16899974 and DDAH1 rs997251 SNPs with incidence of coronary artery disease (CAD) in Egyptians and to correlate these variants with the serum levels of ADMA and SDMA. The study included 150 subjects; 100 CAD patients and 50 healthy controls. Genotyping was performed by qPCR while the ADMA and SDMA concentrations were assayed by ELISA. Both serum ADMA and SDMA concentrations were significantly higher in CAD patients compared to controls (both p < 0.0001). Genotype distributions for all studied SNPs were significantly different between CAD patients and controls. Carriers of AGXT2 rs37369-T allele (CT + TT genotypes) and AGXT2 rs16899974-A allele (CA + AA genotypes) had 2.4- and 2.08-fold higher risk of having CAD than CC genotype in both SNPs (p = 0.0050 and 0.0192, respectively). DDAH1 rs997251 TC + CC genotypes were associated with 2.3-fold higher risk of CAD than TT genotype (p = 0.0063). Moreover, the AGXT2 rs37369 TT and AGXT2 rs16899974 AA genotypes were associated with the highest serum ADMA and SDMA while DDAH1 rs997251 CC genotype was associated with the highest ADMA. AGXT2 rs37369-T, AGXT2 rs16899974-A, and DDAH1 rs997251-C alleles represent independent risk factors for CAD in the Egyptians.
- 18 May 2016
- Published by Taylor & Francis in Nutritional Neuroscience
- Vol. 20 (8) , 443-448
Investigation of brain-derived neurotrophic factor (BDNF) gene expression in hypothalamus of obese rats: Modulation by omega-3 fatty acids
Purpose: The aim of this study was investigating the effect of omega-3 fatty acids (ω-3 FAs) on brain-derived neurotrophic factor (BDNF) gene expression, using in vivo and in vitro models, to unravel the potential mechanisms of polyunsaturated fatty acids use in obesity. Materials and methods: Twenty-nine Sprague-Dawley rats were divided into three groups; lean controls fed normal chow diet for 14 weeks, obese controls fed 60% of their diet as saturated fats for 14 weeks, and ω-3 FAs-treated rats fed 60% saturated fat diet for 14 weeks with concomitant oral administration of 400 mg/kg/day ω-3 FAs, mainly docosahexaenoic acid and EPA, from week 12 to week 14. For the in vitro experiment, hypothalamic cells from six obese rats were cultured in the presence of different concentrations of ω-3 FAs to determine its direct effect on BDNF expression. Results: In vivo results showed that obesity has negative effect on BDNF gene expression in rat hypothalamus that was reversed by administration of ω-3 FAs. Obese rats showed hypercholesterolemia, hypertriglyceridemia, normoinsulinemia, hyperglycemia and hyperleptinemia. Treatment with ω-3 FAs showed significant decrease in serum total cholesterol and TAG. Also serum glucose level and HOMA index were decreased significantly. In vitro results demonstrated the increase in BDNF expression by ω-3 FAs in a dose-dependent manner. Conclusions: Obesity causes down-regulation of BDNF gene expression that can be reversed by ω-3 FAs treatment, making them an interesting treatment approach for obesity and metabolic disease.
- 18 May 2016
- Published by Taylor & Francis in Nutritional Neuroscience
- Vol. 20 (8) , 443-448
Investigation of brain-derived neurotrophic factor (BDNF) gene expression in hypothalamus of obese rats: Modulation by omega-3 fatty acids
Purpose: The aim of this study was investigating the effect of omega-3 fatty acids (ω-3 FAs) on brain-derived neurotrophic factor (BDNF) gene expression, using in vivo and in vitro models, to unravel the potential mechanisms of polyunsaturated fatty acids use in obesity. Materials and methods: Twenty-nine Sprague-Dawley rats were divided into three groups; lean controls fed normal chow diet for 14 weeks, obese controls fed 60% of their diet as saturated fats for 14 weeks, and ω-3 FAs-treated rats fed 60% saturated fat diet for 14 weeks with concomitant oral administration of 400 mg/kg/day ω-3 FAs, mainly docosahexaenoic acid and EPA, from week 12 to week 14. For the in vitro experiment, hypothalamic cells from six obese rats were cultured in the presence of different concentrations of ω-3 FAs to determine its direct effect on BDNF expression. Results: In vivo results showed that obesity has negative effect on BDNF gene expression in rat hypothalamus that was reversed by administration of ω-3 FAs. Obese rats showed hypercholesterolemia, hypertriglyceridemia, normoinsulinemia, hyperglycemia and hyperleptinemia. Treatment with ω-3 FAs showed significant decrease in serum total cholesterol and TAG. Also serum glucose level and HOMA index were decreased significantly. In vitro results demonstrated the increase in BDNF expression by ω-3 FAs in a dose-dependent manner. Conclusions: Obesity causes down-regulation of BDNF gene expression that can be reversed by ω-3 FAs treatment, making them an interesting treatment approach for obesity and metabolic disease.
- 3 September 2014
- Published by Taylor & Francis in Journal of Receptors and Signal Transduction
- Vol. 35 (5) , 391-395
Vitamin D receptor gene polymorphisms (TaqI and ApaI) in relation to 25-hydroxyvitamin D levels and coronary artery disease incidence
Context/objective: Previous studies have illustrated the association of the ApaI and TaqI polymorphisms of the vitamin D receptor gene, located in non-coding and coding regions, respectively, with diseases such as cancer and cardiovascular disease; however, investigating such association in Egyptian patients with coronary artery disease (CAD) has never been formerly attempted. Materials and methods: Male patients (n = 137), 35–50 years of age, with verified CAD, were recruited alongside age- and sex-matched controls (n = 58). Genotyping and 25-hydroxyvitamin D [25(OH)D] measurement were performed by polymerase chain reaction RFLP and HPLC, respectively. Results: Comparison of the genotypic distribution of both the TaqI and ApaI polymorphisms between patients and controls yielded insignificant results (p = 0.55 and 0.7, respectively). Comparison of the allelic distribution of both polymorphisms also yielded insignificant results. The TaqI polymorphism was not found to predict 25(OH)D levels, whereas the wild-type genotype of the ApaI polymorphism was associated with greater levels of 25(OH)D (p = 0.02), taking all subjects into consideration. Discussion/conclusion: This study presents the ApaI and TaqI polymorphisms as non-influencing players in the pathogenesis of CAD in Egyptian males and the ability of only the ApaI polymorphism to predict 25(OH)D levels, thus warranting further investigations of the triangular relationship between the polymorphisms, 25(OH)D and CAD incidence.
- 3 September 2014
- Published by Taylor & Francis in Journal of Receptors and Signal Transduction
- Vol. 35 (5) , 391-395
Vitamin D receptor gene polymorphisms (TaqI and ApaI) in relation to 25-hydroxyvitamin D levels and coronary artery disease incidence
Context/objective: Previous studies have illustrated the association of the ApaI and TaqI polymorphisms of the vitamin D receptor gene, located in non-coding and coding regions, respectively, with diseases such as cancer and cardiovascular disease; however, investigating such association in Egyptian patients with coronary artery disease (CAD) has never been formerly attempted. Materials and methods: Male patients (n = 137), 35–50 years of age, with verified CAD, were recruited alongside age- and sex-matched controls (n = 58). Genotyping and 25-hydroxyvitamin D [25(OH)D] measurement were performed by polymerase chain reaction RFLP and HPLC, respectively. Results: Comparison of the genotypic distribution of both the TaqI and ApaI polymorphisms between patients and controls yielded insignificant results (p = 0.55 and 0.7, respectively). Comparison of the allelic distribution of both polymorphisms also yielded insignificant results. The TaqI polymorphism was not found to predict 25(OH)D levels, whereas the wild-type genotype of the ApaI polymorphism was associated with greater levels of 25(OH)D (p = 0.02), taking all subjects into consideration. Discussion/conclusion: This study presents the ApaI and TaqI polymorphisms as non-influencing players in the pathogenesis of CAD in Egyptian males and the ability of only the ApaI polymorphism to predict 25(OH)D levels, thus warranting further investigations of the triangular relationship between the polymorphisms, 25(OH)D and CAD incidence.